Reported 6 months ago
Stocks of companies like Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics are experiencing a decline due to positive results from Roche Holdings' CT-996 trial for type 2 diabetes and obesity, showing significant weight loss. Viking Therapeutics also demonstrated promising results with VK2735, while Eli Lilly's Mounjaro users experienced substantial weight loss compared to Novo Nordisk's Ozempic users. Structure Therapeutics' GSBR-1290 also showed a significant weight loss decrease, causing a drop in the aforementioned companies' stock prices.
Source: YAHOO